Please upgrade your browser.
UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine
The phase 3 trial at the UNM Cancer Center tests a promising new approach: it uses a person's own kidney cancer cells to make a vaccine tailored to kill those cells.
Preclinical data indicates that lead investigational compound PT2385 suppresses gene expression essential for tumor growth, proliferation, and angiogenesisPhase 1 study of PT2385 ongoing; first clinical stage HIF-2a program.
Kidney cancer is typically aggressive and difficult to manage and treat. There are often no symptoms of the disease in its early stages, which unfortunately allows the cancer time to grow and spread. When caught early, surgical removal of the kidney or kidneys can be curative. If the disease has spread or metastasized, there is no known effective treatment, though there are treatments that can prolong life and slow the progression of the disease.
George, who retired as Chicago archbishop in the fall of 2014, a few months before announcing his treatment for kidney cancer had failed, died late Friday morning, according to the Archdiocese of Chicago.
WTX may modulate tumorigenesis and cell differentiation in part through its effect on chromatin regulation.
A patient friendly summary of the most recent international symposium is available online, on the Kidney Cancer Association's web page for medical education. The summary was produced and edited by KCA director Michael B. Lawing.
Give STL Day is an online national day of giving to the community, organized by the local Greater St. Louis Community Foundation. On May 5, you can go to https://www.givestlday.org/#npo/bialeckikidney-cancer-foundation and designate, easily and safely, your gift to the Bialecki Kidney Cancer Foundation which supports the Kidney Cancer Association. More information can be found in the full news story below.
The fast track designation is designed to expedite the review process for treatments of fatal diseases that do not already have viable alternatives for treatment. With the designation, cabozantinib is now also eligible for a Priority Review of a New Drug Application.
Imagine the devastation of learning you have cancer, and then imagine being told it has advanced and already spread to other areas of your body
|Powered by NeonCRM|